Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (86)	9/3/1998 9:04:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1073

Rick: >>CRXA also has a diagnostic position with Her-2?? I'm not certain of that, but......<< Corixa have diagnostic division, but I didn't hear about Her-diagnostic. Their Her-vaccines are proteins from receptor epitopes, so my question is: Can they develop kit based on this proteins? >>Also relevant to this thread, OSIP is planning to launch a Her-2 diagnostic. So, Oncor, Corixa, OSI Pharmaceuticals...... is anyone else climbing on the GNE bandwagon?<< As far as I know, Oncor and OSIP are the only competitors. Of topic: I do not follow CTIC, so do not know much about CT-2584. Maybe it is time to do dd. Miljenko